| Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations (NCT01977521) | Iris Sommer | 2014-04-01 |
| Problem-solving-based Bibliotherapy Program for Family Caregivers (NCT02391649) | Chinese University of Hong Kong | 2014-03-01 |
| Group Training for Social Skills in Psychosis (NCT02181777) | King's College London | 2014-03-01 |
| Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (NCT02087579) | Janssen Research & Development, LLC | 2014-02-01 |
| Irish Omega-3 Study (NCT02848469) | University College Cork | 2013-09-01 |
| Motivational Intervention for Physical Activity in Psychosis (NCT02648321) | The University of Hong Kong | 2013-09-01 |
| The Family VOICE Study (NCT01804582) | University of Maryland, Baltimore | 2013-05-01 |
| Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness (NCT01779440) | Dartmouth-Hitchcock Medical Center | 2013-01-01 |
| Cannabinoids and Cerebellar-Motor Functioning (NCT01853020) | Yale University | 2012-12-01 |
| Lifestyle Intervention for Diabetes and Weight Management in Psychosis (NCT01828931) | Centre for Addiction and Mental Health | 2012-12-01 |
| Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (NCT01739127) | University of British Columbia | 2012-11-01 |
| Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis (NCT01688765) | Mclean Hospital | 2012-10-17 |
| Antipsychotic to Treat Psychosis Syndrome (NCT02137616) | Central South University | 2012-06-01 |
| Antipsychotics and Risk of Hyperglycemic Emergencies (NCT02582736) | Canadian Network for Observational Drug Effect Studies, CNODES | 2012-04-01 |
| A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention (NCT05012709) | Jianan Psychiatric Center, Ministry of Health and Welfare | 2012-03-15 |
| Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations (NCT01512290) | UMC Utrecht | 2012-03-01 |
| Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI) (NCT00983476) | VA Office of Research and Development | 2012-03-01 |
| Cognitive Therapy for Distressing Visual Hallucinations: A Pilot Study (NCT02782507) | Newcastle University | 2012-01-01 |
| The Topical Niacin Skin Flush Test in First Episode Psychosis (NCT01324297) | Nova Scotia Health Authority | 2011-12-01 |
| Bergen Psychosis Project 2 - The Best Intro Study (NCT01446328) | Haukeland University Hospital | 2011-10-01 |
| Improving Outcomes for Individuals With Serious Mental Illness and Diabetes (NCT01410357) | Case Western Reserve University | 2011-07-01 |
| Mental Health Related to School Dropout in Luxembourg (NCT01354236) | Public Research Centre Health, Luxembourg | 2011-01-01 |
| Supported Employment: Motivational Enhancement for Entry and Outcome (NCT01041976) | VA Office of Research and Development | 2011-01-01 |
| Monitoring and Management for Metabolic Side Effects of Antipsychotics (NCT01875861) | VA Office of Research and Development | 2011-01-01 |
| Adult Study Oxytocin - Behavioral (NCT02567032) | University of California, San Francisco | 2010-10-01 |
| Epidemiology Study of Psychosis (NCT01423669) | The University of Hong Kong | 2010-08-01 |
| Optimal Duration of Early Intervention for Psychosis (NCT01202357) | The University of Hong Kong | 2010-07-01 |
| Acute Glycine Pharmacodynamic Study (NCT01610011) | Mclean Hospital | 2010-07-01 |
| A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs) (NCT00677898) | US Department of Veterans Affairs | 2010-03-01 |
| Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention (NCT00980252) | University of Illinois at Chicago | 2009-11-01 |
| Extended Specialized Assertive Intervention for First Episode Psychosis (NCT00914238) | University of Copenhagen | 2009-07-01 |
| Stage-specific Case Management for Early Psychosis (NCT00919620) | The University of Hong Kong | 2009-06-01 |
| Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) (NCT00790517) | Kaiser Permanente | 2009-06-01 |
| D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia (NCT00960219) | China Medical University Hospital | 2009-04-01 |
| Effects of Delta-9-THC and Iomazenil in Healthy Humans (NCT00982982) | Yale University | 2009-02-11 |
| A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder (NCT01094249) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-02-01 |
| Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (NCT00806234) | Johns Hopkins University | 2009-01-01 |
| Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia (NCT00821600) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-12-01 |
| Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up (NCT02526030) | Fundación Marques de Valdecilla | 2008-10-01 |
| Psychiatric Genotype/Phenotype Project Repository (NCT00762866) | Vanderbilt University | 2008-09-01 |
| Forensic Assertive Community Treatment: An Emerging Model of Service Delivery (NCT01313052) | University of Rochester | 2008-05-01 |
| Cannabinoids, Neural Synchrony, and Information Processing (NCT00708994) | Yale University | 2008-02-25 |
| Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study (NCT01924715) | Nova Scotia Health Authority | 2008-01-01 |
| Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia (NCT00936351) | US Department of Veterans Affairs | 2007-12-01 |
| Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder (NCT00541502) | Genovate Biotechnology Co., Ltd., | 2007-11-01 |
| Early Detection and Intervention for the Prevention of Psychosis (NCT00531518) | MaineHealth | 2007-10-01 |
| Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease (NCT00535145) | Ortho-McNeil Janssen Scientific Affairs, LLC | 2007-10-01 |
| Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis (NCT00484302) | Bispebjerg Hospital | 2007-09-01 |
| Effect of Antipsychotics on Appetite Regulation (NCT00903916) | University of North Carolina, Chapel Hill | 2007-08-01 |
| Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder (NCT00457899) | AstraZeneca | 2007-07-01 |
| Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders (NCT00508560) | US Department of Veterans Affairs | 2007-07-01 |
| Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. (NCT00488319) | Janssen Research & Development, LLC | 2007-06-01 |
| Anticholinergic Burden in Schizophrenia (NCT00715377) | Centre for Addiction and Mental Health | 2007-06-01 |
| Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis (NCT00465920) | University of Cologne | 2007-05-01 |
| FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis (NCT00486798) | AstraZeneca | 2007-05-01 |
| A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment (NCT00420823) | Melbourne Health | 2007-01-01 |
| Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects (NCT00567034) | Mclean Hospital | 2006-12-01 |
| Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order (NCT00282165) | UMC Utrecht | 2006-11-01 |
| Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia (NCT00276263) | Herzog Hospital | 2006-08-01 |
| First Episode Schizophrenia and Cannabis-Related Disorder Study (NCT00573287) | Dartmouth-Hitchcock Medical Center | 2006-06-01 |
| Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II (NCT00377117) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2006-05-01 |
| Side Effects of Antipsychotic Medications (NCT00363181) | Stanford University | 2006-04-01 |
| Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis (NCT00307216) | University of North Carolina, Chapel Hill | 2006-04-01 |
| A Clinical Trial on the Antipsychotic Properties of Cannabidiol (NCT00309413) | University of Cologne | 2006-03-01 |
| Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis (NCT00369239) | Janssen Pharmaceutica N.V., Belgium | 2006-03-01 |
| Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia (NCT00299702) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-02-01 |
| Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication (NCT00287027) | National Alliance on Mental Illness New Hampshire | 2006-02-01 |
| Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment (NCT00783185) | University of Konstanz | 2006-01-01 |
| Culturally Responsive Person-Centered Care for Psychosis (NCT00231933) | Yale University | 2005-10-01 |
| Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis (NCT02305823) | Fundación Marques de Valdecilla | 2005-10-01 |
| Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up (NCT02534363) | Fundación Marques de Valdecilla | 2005-10-01 |
| Rapid Tranquillization Trial: TREC-India II (NCT00455234) | Christian Medical College, Vellore, India | 2005-09-01 |
| Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder (NCT00130923) | Dartmouth-Hitchcock Medical Center | 2005-09-01 |
| Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) (NCT00844922) | Merck Sharp & Dohme LLC | 2005-09-01 |
| Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine (NCT00224302) | Central Institute of Mental Health, Mannheim | 2005-08-01 |
| An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression (NCT00128505) | Corcept Therapeutics | 2005-08-01 |
| Clinical and Biological Characteristics of Psychotic Depression (NCT00576095) | Stanford University | 2005-08-01 |
| Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease (NCT00125138) | Lundbeck LLC | 2005-07-01 |
| A Brief Community Linkage Intervention for Dually Diagnosed Individuals (NCT00137267) | US Department of Veterans Affairs | 2005-06-01 |
| A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents (NCT00163865) | Bayside Health | 2005-05-01 |
| A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) (NCT00216632) | Janssen Pharmaceutica N.V., Belgium | 2005-03-01 |
| Functional Rehabilitation of Older Patients With Schizophrenia (NCT00237796) | US Department of Veterans Affairs | 2005-02-01 |
| Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia (NCT00491569) | China Medical University Hospital | 2005-01-01 |
| The Immune System and Psychiatric Disorders (NCT00184418) | Norwegian University of Science and Technology | 2005-01-01 |
| Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia (NCT00328276) | China Medical University Hospital | 2004-12-01 |
| Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone (NCT00174200) | Pfizer | 2004-12-01 |
| Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder (NCT00137020) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-11-01 |
| A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder (NCT00216476) | Janssen-Cilag International NV | 2004-10-01 |
| A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis (NCT00246259) | Janssen-Ortho Inc., Canada | 2004-10-01 |
| Fast Titration Of Quetiapine Versus Currently Approved Titration (NCT00254813) | AstraZeneca | 2004-10-01 |
| Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia (NCT00158223) | Icahn School of Medicine at Mount Sinai | 2004-10-01 |
| Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone (NCT00563017) | Hospital Authority, Hong Kong | 2004-10-01 |
| A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression (NCT00128479) | Corcept Therapeutics | 2004-09-01 |
| Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population (NCT00253240) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2004-09-01 |
| Safety Study of ORG 34517 for Major Depression With Psychotic Features (NCT00226278) | Weill Medical College of Cornell University | 2004-09-01 |
| A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression (NCT00130676) | Corcept Therapeutics | 2004-09-01 |
| Antipsychotic Discontinuation in Alzheimer's Disease (NCT00417482) | New York State Psychiatric Institute | 2004-08-01 |
| A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) (NCT00212797) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Psychiatric Advance Directives for Improved Mental Health Care (NCT00105794) | US Department of Veterans Affairs | 2004-03-01 |
| Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms (NCT00169988) | Northwell Health | 2004-03-01 |